GlassScriptPhysician profile
Laurier A Vocal
NPI 1821102005
$8,163.75
in general payments reported to CMS, 2019-2025
49 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $714 · 2021: $1,075 · 2022: $1,206 · 2023: $2,231 · 2024: $473 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185 · Debt Forgiveness: $18.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.70 |
| Debt Forgiveness | $18.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $984.27 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $897.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $686.03 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $627.13 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $516.12 | 2019-2023 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.09 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $394.57 | 2019-2023 | |
| Abbvie INC. | $327.85 | 2020-2023 | Mavyret |
| Abbott Laboratories | $313.82 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Amarin Pharma, INC. | $289.24 | 2019-2021 | |
| Nalu Medical, INC. | $241.83 | 2023 | Nalu Neurostimulation System |
| Merck Sharp & Dohme LLC | $217.71 | 2019-2021 | |
| Corcept Therapeutics | $179.74 | 2024-2025 | Korlym |
| Shockwave Medical, INC | $176.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.25 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurier Vocal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.